InkVivo integrates its proprietary polymer platform with AI predictive modeling to accelerate drug formulation and de-risk clinical outcomes. This combined materials-science and data-driven approach is supported by early human data demonstrating improved pharmacokinetic profiles with prolonged systemic exposure.
The company is advancing two internal programs targeting high-value indications: anemia (clinical stage) and dementia (preclinical), while leveraging its platform through a capital-efficient B2B model. InkVivo has secured two external partnerships to expand into additional applications, validating both technology and market demand.
Supported by experienced investors, a multidisciplinary team, and a strong IP, InkVivo is positioned as a key enabler of next generation therapeutics.
News
